

(11) **EP 0 759 441 A2**(12) **EUROPEAN PATENT APPLICATION**(43) Date of publication:
26.02.1997 Bulletin 1997/09(51) Int Cl.⁶ **C07K 14/47, A61K 38/17**
// (A61K38/17, 31:00),
(A61K38/17, 31:445)(21) Application number: **96304723.8**(22) Date of filing: **26.06.1996**(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE
 Designated Extension States:
AL LT LV SI(30) Priority: **30.06.1995 US 740**
27.10.1995 US 5910
30.06.1995 US 752
27.10.1995 US 5911(71) Applicant: **ELI LILLY AND COMPANY**
Indianapolis, Indiana 46285 (US)(72) Inventors:

- **Bue-Valleskey, Juliana Maude**
Indianapolis, Indiana 46220 (US)
- **Helman, Mark Louis**
Indianapolis, Indiana 46250 (US)
- **Stephens, Thomas Wesley**
Indianapolis, Indiana 46226 (US)
- **Tinsley, Frank C.**
Indianapolis, Indiana 46256 (US)

(74) Representative: **Tapping, Kenneth George et al**
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)(54) **Methods of treating neuropeptide Y-associated conditions**

(57) This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neu-

ropeptide Y which comprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

BEST AVAILABLE COPY**EP 0 759 441 A2**